Abstract
A novel, potent, and orally bioavailable inhibitor of the bromodomain of CBP, compound 35 (GNE-207), has been identified through SAR investigations focused on optimizing al bicyclic heteroarene to replace the aniline present in the published GNE-272 series. Compound 35 has excellent CBP potency (CBP IC50 = 1 nM, MYC EC50 = 18 nM), a selectively index of >2500-fold against BRD4(1), and exhibits a good pharmacokinetic profile.
Keywords:
Bromodomain; CBP inhibitor; Half-life; Volume of distribution.
Copyright © 2017 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Binding Sites
-
Biphenyl Compounds / chemical synthesis
-
Biphenyl Compounds / chemistry*
-
Biphenyl Compounds / metabolism
-
Cell Cycle Proteins
-
Crystallography, X-Ray
-
Drug Design*
-
Half-Life
-
Humans
-
Hydrogen Bonding
-
Inhibitory Concentration 50
-
Mice
-
Microsomes, Liver / metabolism
-
Molecular Dynamics Simulation
-
Nuclear Proteins / antagonists & inhibitors
-
Nuclear Proteins / metabolism
-
Protein Structure, Tertiary
-
Rats
-
Structure-Activity Relationship
-
Transcription Factors / antagonists & inhibitors
-
Transcription Factors / metabolism
-
p300-CBP Transcription Factors / antagonists & inhibitors*
-
p300-CBP Transcription Factors / metabolism
Substances
-
BRD4 protein, human
-
Biphenyl Compounds
-
Cell Cycle Proteins
-
Nuclear Proteins
-
Transcription Factors
-
diphenyl
-
p300-CBP Transcription Factors